A method of determining the concentration of at least one analyte in a plurality of samples by sequentially subjecting each sample to an analysis cycle comprises contacting the sample or a sample-derived solution with a sensor surface supporting a species capable of specifically binding the analyte or an analyte-binding species, detecting the amount of binding to the sensor surface, and regenerating the sensor surface to prepare it for the next analytical cycle, and based on the detected binding to the sensor surface determining the concentration of analyte in each sample using virtual calibration data calculated for each analysis cycle from real calibration data obtained by contacting the solid phase with samples containing known concentrations of analyte.

A diagnostic assay strip includes a first layer that includes an iron mobile labelled specific binding partner that will bind to and iron biomarker from a sample and produce an iron complex and a vitamin A mobile labelled specific binding partner that will bind to a vitamin A biomarker from the sample and produce a vitamin A complex. A second layer includes iron and vitamin A test regions, and a control region. The iron test region has immobilized specific binding partners that will bind to the iron complex. The vitamin A test region has immobilized vitamin A biomarker that will bind to vitamin A mobile labelled specific binding partner, which is not bound to the vitamin A biomarker, passing from the first layer to the second layer. The control region has a moiety which will non-specifically bind to and immobilize the iron and vitamin A labelled specific binding partners. Methods of using the diagnostic assay strip are also discussed.

A microfluidic device is provided for conducting multiplex immunoassays to detect multiple target analytes in a liquid sample using a set of tags and anti-tags. The device comprises an array of different anti-tags immobilised on a surface of a sensor for measuring a signal. Each anti-tag is arranged to immobilise a tagged antibody or tagged antigen thereby in use separating tagged immune complexes from the liquid phase affecting the signal measured. The device comprises a sensor chamber for tagged immune complexes to form in the liquid phase and one or more detection zones each comprising the array of different anti-tags for immobilising tagged immune complexes. In use, liquid comprising the tagged immune complexes flows or is fluidically driven from the sensor chamber to the detection zone(s).

The problem addressed by the present invention is to provide an immunological assay method using a monoclonal antibody and a kit including the monoclonal antibody, which can be used for assaying ICTP without requiring special facilities. This problem can be solved by a method for immunological assay of type I collagen C-terminal telopeptide in a biological sample, including contacting type I collagen C-terminal telopeptide with a monoclonal antibody that recognizes an amino acid sequence represented by GFDFSFLP (SEQ ID NO: 1) as an epitope.

The present invention relates to monoclonal antibodies that target collagen type XIX, and to immunoassays and kits employing the antibodies. The assays of the invention can be used in the diagnosis and monitoring of cancer.

The present disclosure relates generally to compositions and methods for assaying antibodies. More specifically, the disclosure relates to assays that detect antibodies that have neutralizing activity against SARS-CoV-2.

An object of the present invention is to provide a kit for quantitatively determining a bile acid, in which it is possible to improve measurement accuracy by sufficiently dissociating the bile acid from a polymer component, and to rapidly carry out the quantitative determination of the bile acid with high accuracy under various environments, and a method for quantitatively determining the bile acid.

According to the present invention, a kit for quantitatively determining a bile acid in a biological sample, including a compound represented by General Formula (I) defined in the present specification in a dry state; a fluorescent particle that has a first binding substance capable of binding to the bile acid; and a substrate that has a detection region having a second binding substance capable of binding to any one of the bile acid and the first binding substance, is provided.

A microdevice includes: a microchannel to which a measurement target solution containing a measurement target substance is introduced; an antibody being fixed to at least one sidewall surface of the microchannel and specifically binding to the measurement target substance; a fluorescence-labeled derivative being specifically bound to the antibody and being acquired by fluorescence-labeling the measurement target substance; and a light blocker blocking excitation light exciting fluorescent light radiated by the fluorescence-labeled derivative. The measurement target substance and the fluorescence-labeled derivative specifically bind to the antibody in a competitive manner, and the antibody is fixed to the sidewall surface of the microchannel in a state of specifically binding to the fluorescence-labeled derivative. The light blocker blocks the excitation light entering the fluorescence-labeled derivative specifically binding to the antibody.

Provided herein are methods and corresponding compounds for treating fibrotic disease by administering to a subject a compound of Formula I or pharmaceutically acceptable salt thereof, which inhibits phosphorylation of Smad2/3, according to Phospho-Smad2/3 Inhibition Assay, and is inactive according to MAPK p38 Activation Assay; or a compound of Formula II or III. Also provided are methods and corresponding compounds for treating cancers, inflammatory diseases, rasopathies and autoimmune leukoproliferative disorders.

The present invention provides a recombinant thyroid stimulating hormone receptor protein, a preparation method therefor and an application thereof. The recombinant thyroid stimulating hormone receptor protein comprises a TSHR protein extracellular segment and a TSHR protein intracellular segment. The C-terminus of the TSHR protein extracellular segment is linked to the N-terminus of the TSHR protein intracellular segment. The protein achieves extracellular soluble expression, and is high in purity, high in activity and good in stability.